HLA class II typed cells to accelerate effective research on immunotherapies
We support effective research on immunotherapies by expanding the range of HLA-types provided for all Human Primary Cells and Blood & Stem Cells. In addition to the MHC class I genes HLA-A, -B, and -C, we now also offer 4-digit resolution for MHC class II genes HLA-DPA1/DPB1, -DQA1/DQB1, and -DRB1/DRB345.
The Human Leukocyte Antigen (HLA) system plays a fundamental role in the determination of histocompatibility between different individuals and regulation of the human immunity….
Go To Page
Histocompatibility: Piecing together the immunotherapy puzzle
What do puzzles and immunity have in common? The human leukocyte antigen (HLA) system of cell-surface proteins help to regulate the immune system. Yet particular antigens can make a crucial difference. Patients with certain HLA types are more likely to have autoimmune diseases, contract infectious disease or develop cancer. Now, through better understanding of HLA function,…
Go To Page
For faster research on immunotherapies: HLA-typed human primary cells
– HLA-typed human primary cells for researchers across the world
– Great tool in the development and testing of new cancer drugs
– HLA-typed donor characteristics are precisely documented…
Go To Page
The importance of HLA for the development of cell therapies
Thanks to a greater understanding of human leukocyte antigen (HLA) function, researchers can now work toward developing new cancer immunotherapies….
Go To Page
Could HLA-type be the answer to individual differences in COVID-19 severity?
The COVID-19 pandemic has changed the world. While vaccines are now being approved, a true understanding of the biological processes underlying COVID-19 and why some individuals develop severe disease while others are asymptomatic is necessary. HLA-type could be a key differentiator in disease outcomes, and in developing treatments….
Go To Page
Immuno-oncology
A new in vitro strategy Immuno-oncology is a unique combination of oncology and immunology. By activating or amplifying the body’s natural defenses, immuno-oncology aims to boost the immune system to fight cancer better. Targeted antibodies or immunomodulators are well-known immunotherapies; adoptive cell therapy using CAR-T or TCR cells is particularly important,…
Go To Page
PromoCell announces services for large-scale industrial lots of Mesenchymal Stem Cells
– New services for large-scale industrial lots allows customers to have high volumes of standardized MSC populations derived from bone marrow and adipose tissue
– Guaranteed MSC functionality and phenotype in accordance to ISCT* guidelines
– Optimized media with complete supplementation and expert technical support…
Go To Page
Teaching the body to fight tumors using cancer immunotherapy
Selected as the 2013 “Breakthrough of the Year” by Science magazine, cancer immunotherapy shows a completely new way to treat malignancies by using the body’s own immune system, and not by targeting the tumor itself. This cutting-edge area of research and therapy has shown very promising results. However, further investigation is needed to turn immunotherapy into a cancer therapy that can be broadly applied….
Go To Page
Accelerating pre-clinical research with the use of HLA-typed primary cells
In this webinar (~30 min) Dr. Manish Kumar (Product Manager, Cells & Media at PromoCell) will touch base on HLA genetics, its typing, nomenclature and HLA applications in pre-clinical research.…
Go To Page
Stem cell immunotherapy: Harnessing the immune system
Imagine a future where diseases once considered incurable are now within reach of treatment. This is the promise of stem cell immunotherapy, a rapidly evolving approach that harnesses the unique properties of pluripotent cells to revolutionize medical treatments.1 From autoimmune diseases to cancer, the potential of stem cell immunotherapy is vast and transformative. …
Go To Page
Studying oxidative stress and skin aging using in vitro human cell culture models
Oxidative stress results from an imbalance of pro- and anti-oxidants and leads to faster skin aging, inflammation and disease. Cell assays and primary cells provide the tools researchers need to study the oxidative process and its association with skin aging….
Go To Page
Branching out: In vitro angiogenesis advancements
In this interview with RegMedNet, our expert, Iris Bischoff-Kont, discusses the latest advancements in angiogenesis research and their potential applications in regenerative medicine. Dr Bischoff-Kont also explores the challenges faced in translating angiogenesis research findings into clinical therapies and the importance of understanding the crosstalk between angiogenesis and other processes like inflammation….
Go To Page